Cetuximab Paired With Dye Can Image Glioblastoma Cetuximab Paired With Dye Can Image Glioblastoma
The antibody cetuximab paired with a fluorescent dye can image glioblastoma during brain surgery, a pilot study showed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2017 Category: Consumer Health News Tags: General Surgery News Source Type: news
Vanderbilt researchers find novel mechanism of resistance to anti-cancer drugs
(Vanderbilt University Medical Center) Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported Oct. 16 in Nature Medicine, suggest a strategy for overcoming this resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news
NICE recommends Merck ’s erbitux to treat R/M SCCHN in oral cavity
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Merck ’s erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat recurrent and / or metastatic (R/M) squamous cell carcinoma of t… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news
Results of NRG-RTOG 0436 highlight need for biomarkers in treatment of esophageal cancer
(NRG Oncology) NRG-RTOG 0436 has determined that adding an epidermal growth factor receptor (EGFR) inhibitor to a chemo-radiation regimen does not improve overall survival for patients with locally advanced esophageal cancer treated in a non-operative manner. These results are reported in 'Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients with Esophageal Cancer -- The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial,' which was recently published in the Journal of the American Medical Association Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 25, 2017 Category: International Medicine & Public Health Source Type: news
Erbitux (Cetuximab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 21, 2017 Category: Drugs & Pharmacology Source Type: news
Adding Cetuximab in Esophageal Cancer Fails to Improve Survival
Use of the EGFR inhibitor cetuximab with chemoradiation did not improve survival in patients with esophageal carcinoma compared with chemoradiation alone, according to the results of the phase III RTOG 0436 trial. (Source: CancerNetwork)
Source: CancerNetwork - July 13, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Esophageal Cancer Gastrointestinal Cancer News Source Type: news
SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in HNC
(InSilico Medicine, Inc.) The researchers identified that SMAD4 loss results in cetuximab resistance in vitro and poor survival in HPV-negative HNSCC patients and in vivo models. Using OncoFinder (an innovative bioinformatic tool currently rebranded as iPANDA), they revealed a signature of pro-survival and anti-apoptotic pathways specifically dysregulated in SMAD4-low HNSCCs and indicate JNK and MAPK activation as potential mediators of cetuximab resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 7, 2017 Category: International Medicine & Public Health Source Type: news
Oh, Lovely: The Tick That Gives People Meat Allergies Is Spreading
By Megan Molteni for WIRED.
First comes the unscratchable itching, and the angry blossoming of hives. Then stomach cramping, and — for the unluckiest few — difficulty breathing, passing out, and even death. In the last decade and a half, thousands of previously protein-loving Americans have developed a dangerous allergy to meat. And they all have one thing in common: the lone star tick.
Red meat, you might be surprised to know, isn’t totally sugar-free. It contains a few protein-linked saccharides, including one called galactose-alpha-1,3-galactose, or alpha-gal, for short. More and more people are lear...
Source: Healthy Living - The Huffington Post - June 20, 2017 Category: Consumer Health News Source Type: news
Adding vemurafenib doubles progression-free survival in BRAF metastatic colorectal cancer
(University of Colorado Anschutz Medical Campus) Clinical trial results presented in an oral abstract session 3:00pm Monday, June 5 at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 shows promising results for the addition of vemurafenib (anti-BRAF) to treatment with cetuximab and irinotecan (anti-EGFR) in patients with metastatic colorectal cancer that have a BRAF V600E mutation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: news
NICE recommends Merck ’s Erbitux to treat patients with metastatic colorectal cancer
The UK National Institute for Health and Care Excellence (NICE) has issued a positive final appraisal determination (FAD) for Merck ’s Erbitux (cetuximab) to treat patients with RAS wild-type metastatic colorectal cancer (mCRC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 3, 2017 Category: Pharmaceuticals Source Type: news
Addition of Vemurafenib to Irinotecan/Cetuximab Delayed Progression in BRAF-Mutated mCRC
The addition of the BRAF inhibitor vemurafenib to irinotecan and cetuximab prolonged progression-free survival and resulted in a higher disease control rate than treatment with irinotecan and cetuximab alone in patients with BRAF-mutant metastatic colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Colorectal Cancer News Source Type: news
Vemurafenib Delayed Progression in Metastatic, BRAF-Mutant CRC
This video covers results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 23, 2017 Category: Cancer & Oncology Authors: Scott Kopetz, MD Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Videos Gastrointestinal Cancers Source Type: news
Cetuximab Reduces Locoregional Failure in Anal Canal Carcinoma, Adds Toxicity
Adding cetuximab to chemoradiation yielded better locoregional failure rates than historical data in a small trial of patients with squamous cell carcinoma of the anal canal, but the treatment resulted in substantial toxicity. (Source: CancerNetwork)
Source: CancerNetwork - January 11, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer News Source Type: news
[Research Article] The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
The kinase AXL promotes cetuximab resistance by promoting the nuclear accumulation of EGFR. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - January 3, 2017 Category: Science Authors: Toni M. Brand, Mari Iida, Kelsey L. Corrigan, Cara M. Braverman, John P. Coan, Bailey G. Flanigan, Andrew P. Stein, Ravi Salgia, Jana Rolff, Randall J. Kimple, Deric L. Wheeler Source Type: news
Roadmap to more personalized cancer treatment
People with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation, research has found. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 22, 2016 Category: Science Source Type: news
